Lamellar Biomedical is an innovative biotechnology company, pioneering new approaches for the transfer of functional nucleic acids. The company's unique and versatile LAMELLASOME platform has been designed for the safe and effective delivery of nucleic acid-based therapeutics. Lamellar believes that its LAMELLASOME technology will play a key role in realising the potential of miRNAs, siRNAs, DNA, mRNAs, plasmids and other nucleic acids in development offering the potential to revolutionise the treatment of many rare and intractable diseases.